Long-term safety of drug-coated devices for peripheral revascularisation.

ABSTRACT:

Background

Meta-analyses of randomised trials of paclitaxel-coated peripheral devices found an association with worse long-term survival.

Aims

We aimed to assess long-term mortality in patients treated with drug-coated versus non-drug-coated devices who are insured by Medicare Advantage (MA), an alternative to traditional Medicare that represents >30% of the Medicare eligible population. We analysed data from an MA administrative claims data source that includes both inpatient and outpatient femoropopliteal artery revascularisation procedures.

Methods

Patients treated with or without drug-coated devices for femoropopliteal artery revascularisation from 4/2015-12/2017 were studied using Optum's De-identified Clinformatics Datamart Database. Mortality was assessed up to

SUBMITTER: Secemsky EA 

PROVIDER: S-EPMC8217425 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature